A rare mutation in the F12 gene in a patient with ACE inhibitor-induced angioedema
- 1 June 2017
- journal article
- letter
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 118 (6) , 743-745
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Defective glycosylation of coagulation factor XII underlies hereditary angioedema type IIIJournal of Clinical Investigation, 2015
- Hereditary angioedema with normal C1‐INH with versus without specific F12 gene mutationsAllergy, 2015
- A Randomized Trial of Icatibant in ACE-Inhibitor–Induced AngioedemaNew England Journal of Medicine, 2015
- Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupAllergy, 2014
- Retrospective Study of Drug-induced Anaphylaxis Treated in the Emergency Department or Hospital: Patient Characteristics, Management, and 1-Year Follow-upThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Novel duplication in the F12 gene in a patient with recurrent angioedemaClinical Immunology, 2013
- A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitorClinical Immunology, 2011
- Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitorBiochemical and Biophysical Research Communications, 2006
- Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*Clinical Pharmacology & Therapeutics, 1996